These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 15603341)

  • 21. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
    Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
    Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
    Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn's disease.
    Gologan S; Iacob R; Preda C; Vadan R; Cotruta B; Catuneanu AM; Iacob S; Constantinescu I; Gheorghe L; Iobagiu S; Gheorghe C; Diculescu M
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):39-44. PubMed ID: 22457858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
    Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
    Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnostic tools in inflammatory bowel diseases].
    Bouhnik Y
    Rev Prat; 2005 May; 55(9):977-83. PubMed ID: 16052968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction.
    Vandewalle-El Khoury P; Colombel JF; Joossens S; Standaert-Vitse A; Collot M; Halfvarson J; Ayadi A; Landers CJ; Vermeire S; Rutgeerts P; Targan SR; Chamaillard M; Mallet JM; Sendid B; Poulain D
    Am J Gastroenterol; 2008 Apr; 103(4):949-57. PubMed ID: 18047546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies in inflammatory bowel diseases.
    Kiliç ZM; Tunç B; Ayaz S; Filik L; Aktaş S; Parlak E; Ulker A
    Turk J Gastroenterol; 2004 Dec; 15(4):238-42. PubMed ID: 16249978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease.
    de Vries M; van der Horst-Bruinsma I; van Hoogstraten I; van Bodegraven A; von Blomberg BM; Ratnawati H; Dijkmans B
    J Rheumatol; 2010 Nov; 37(11):2340-4. PubMed ID: 20810508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and Crohn's disease].
    García-Herola A; Nos P; Hoyos M; Hinojosa J; Molés JR; Pascual S; Bustamante M; Sánchez Cuenca JM; Carmona E; Ponce J; Berenguer J
    Gastroenterol Hepatol; 1998 Apr; 21(4):169-73. PubMed ID: 9633176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.
    Jaskowski TD; Litwin CM; Hill HR
    Clin Vaccine Immunol; 2006 Jun; 13(6):655-60. PubMed ID: 16760323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment.
    Teml A; Kratzer V; Schneider B; Lochs H; Norman GL; Gangl A; Vogelsang H; Reinisch W
    Am J Gastroenterol; 2003 Oct; 98(10):2226-31. PubMed ID: 14572572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.
    Israeli E; Grotto I; Gilburd B; Balicer RD; Goldin E; Wiik A; Shoenfeld Y
    Gut; 2005 Sep; 54(9):1232-6. PubMed ID: 16099791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.
    Quinton JF; Sendid B; Reumaux D; Duthilleul P; Cortot A; Grandbastien B; Charrier G; Targan SR; Colombel JF; Poulain D
    Gut; 1998 Jun; 42(6):788-91. PubMed ID: 9691915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody in Iranian patients with inflammatory bowel disease.
    Bahari A; Aarabi M; Aarabi M; Hedayati M; Jarollahi A; Firouzi F; Aghazadeh R; Zali MR; Hashemi M
    Acta Gastroenterol Belg; 2009; 72(3):301-5. PubMed ID: 19902862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease.
    Nisihara RM; de Carvalho WB; Utiyama SR; Amarante H; Baptista ML
    Dig Dis Sci; 2010 Aug; 55(8):2309-15. PubMed ID: 19826949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.
    Paul S; Boschetti G; Rinaudo-Gaujous M; Moreau A; Del Tedesco E; Bonneau J; Presles E; Mounsef F; Clavel L; Genin C; Flourié B; Phelip JM; Nancey S; Roblin X
    J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Assessment of antibodies anti-saccharomyces cerevisiae (ASCA) and autoantibodies in patients with inflammatory bowel disease].
    Beltrão M; Bodas A; Azevedo F; Nunes A; Santos C; Delgado L
    Acta Med Port; 2010; 23(5):829-36. PubMed ID: 21144323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
    Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
    Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
    Vucelic B
    Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.
    Buckland MS; Mylonaki M; Rampton D; Longhurst HJ
    Clin Diagn Lab Immunol; 2005 Nov; 12(11):1328-30. PubMed ID: 16275949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.